Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Spectrum reports updated Phase II data for poziotinib in NSCLC

April 13, 2018 1:38 PM UTC

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) reported updated data from a Phase II trial showing that poziotinib (HM781-36B) led to a confirmed objective response rate (ORR) of 64% in 11 evaluable non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations.

The University of Texas MD Anderson Cancer Center sponsored the trial in collaboration with Spectrum and the Lung Cancer Research Foundation. John Heymach, who is chairman and professor of the department of thoracic/head and neck medical oncology at MD Anderson, said they had initially hoped for response rates of 20-30%. Median progression-free survival (PFS) has not yet been reached at a median follow-up of 6.5 months...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article